Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/27/2019 |
| Start Date: | June 15, 2017 |
| End Date: | March 31, 2019 |
Current Management, Treatment Patterns and Outcomes of Metastatic Castrate Resistant Prostate Cancer Patients Treated With Radium-223
Categorize the clinical parameters and patient determinants that drive physician decision
making for treatment selection including Radium-223 for patients with mCRPC.
making for treatment selection including Radium-223 for patients with mCRPC.
This is a chart review of 200 Xofigo patients to describe sequencing and characterize
clinical parameters and patient determinants that drive physician decision making.
clinical parameters and patient determinants that drive physician decision making.
Inclusion Criteria:
- Patients were diagnosed with bone metastatic castration-resistant prostate cancer
(mCRPC) per medical chart.
- Patients were at least 18 years of age as of the first diagnosis for mCRPC.
- Patients must have received at least one intravenous injection of Radium-223 (Xofigo).
- First injection of Radium-223 must have started between periods
1-January-2014 to 30-June-2014 or 15-November-2014 to present.
- Patients must have a minimum of 12 months documented follow-up records following last
Radium-223 treatment or death within 12 months of last dose.
Exclusion Criteria:
- Patients who received Radium-223 as part in an interventional clinical trial
- Actively treated, or expect to be treated, in 6 months before last follow-up, for any
other malignancy with the exception of non-metastatic skin cancer or low-grade
superficial bladder cancer.
We found this trial at
1
site
Click here to add this to my saved trials
